Which has preferable valuation and earnings, NMRA or MPLT?

Neumora Therapeutics is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neumora Therapeutics N/A N/A -$236.93M -$1.33 N/A Maplight Therapeutics N/A N/A -$161.15M -$40.99 N/A

Is NMRA or MPLT more profitable?

Maplight Therapeutics' return on equity of 0.00% beat Neumora Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Neumora Therapeutics N/A -181.70% -119.15% Maplight Therapeutics N/A N/A N/A

Which has stronger valuation and earnings, NMRA or COAG?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neumora Therapeutics N/A N/A -$236.93M -$1.33 N/A Hemab Therapeutics N/A N/A N/A N/A N/A

Is NMRA or COAG more profitable?

Hemab Therapeutics' return on equity of 0.00% beat Neumora Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Neumora Therapeutics N/A -181.70% -119.15% Hemab Therapeutics N/A N/A N/A

Do analysts recommend NMRA or CALT?

Neumora Therapeutics presently has a consensus price target of $7.67, indicating a potential upside of 330.71%. Given Neumora Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Neumora Therapeutics is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neumora Therapeutics 2 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.56 Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Neumora Therapeutics (NMRA) Competitors

$1.78 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$1.80 +0.02 (+1.01%)

As of 06/12/2026 06:57 PM Eastern

Compare

NMRA vs. MPLT, COAG, CALT, WVE, and COLL

Should you buy Neumora Therapeutics stock or one of its competitors? MarketBeat compares Neumora Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Neumora Therapeutics include Maplight Therapeutics (MPLT), Hemab Therapeutics (COAG), Calliditas Therapeutics AB (publ) (CALT), WAVE Life Sciences (WVE), and Collegium Pharmaceutical (COLL). These companies are all part of the "pharmaceutical products" industry.

How does Neumora Therapeutics compare to Maplight Therapeutics?

Neumora Therapeutics (NASDAQ:NMRA) and Maplight Therapeutics (NASDAQ:MPLT) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability, analyst recommendations and media sentiment.

In the previous week, Maplight Therapeutics had 1 more articles in the media than Neumora Therapeutics. MarketBeat recorded 2 mentions for Maplight Therapeutics and 1 mentions for Neumora Therapeutics. Neumora Therapeutics' average media sentiment score of 1.89 beat Maplight Therapeutics' score of 0.93 indicating that Neumora Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Neumora Therapeutics	Very Positive
Maplight Therapeutics	Positive

Neumora Therapeutics currently has a consensus price target of $7.67, suggesting a potential upside of 330.71%. Maplight Therapeutics has a consensus price target of $37.78, suggesting a potential upside of 36.14%. Given Neumora Therapeutics' higher probable upside, analysts clearly believe Neumora Therapeutics is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neumora Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.56
Maplight Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	3 Strong Buy rating(s)	3.00

47.7% of Neumora Therapeutics shares are held by institutional investors. 26.9% of Neumora Therapeutics shares are held by company insiders. Comparatively, 3.8% of Maplight Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Maplight Therapeutics' return on equity of 0.00% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neumora Therapeutics	N/A	-181.70%	-119.15%
Maplight Therapeutics	N/A	N/A	N/A

Neumora Therapeutics is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.33	N/A
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A

Summary

Maplight Therapeutics beats Neumora Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Neumora Therapeutics compare to Hemab Therapeutics?

Neumora Therapeutics (NASDAQ:NMRA) and Hemab Therapeutics (NASDAQ:COAG) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.33	N/A
Hemab Therapeutics	N/A	N/A	N/A	N/A	N/A

In the previous week, Hemab Therapeutics had 1 more articles in the media than Neumora Therapeutics. MarketBeat recorded 2 mentions for Hemab Therapeutics and 1 mentions for Neumora Therapeutics. Neumora Therapeutics' average media sentiment score of 1.89 beat Hemab Therapeutics' score of 0.93 indicating that Neumora Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Neumora Therapeutics	Very Positive
Hemab Therapeutics	Positive

Neumora Therapeutics presently has a consensus price target of $7.67, suggesting a potential upside of 330.71%. Hemab Therapeutics has a consensus price target of $41.75, suggesting a potential upside of 67.13%. Given Neumora Therapeutics' higher probable upside, equities analysts plainly believe Neumora Therapeutics is more favorable than Hemab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neumora Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.56
Hemab Therapeutics	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Hemab Therapeutics' return on equity of 0.00% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neumora Therapeutics	N/A	-181.70%	-119.15%
Hemab Therapeutics	N/A	N/A	N/A

47.7% of Neumora Therapeutics shares are owned by institutional investors. 26.9% of Neumora Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Neumora Therapeutics beats Hemab Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Neumora Therapeutics compare to Calliditas Therapeutics AB (publ)?

Neumora Therapeutics (NASDAQ:NMRA) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.

Neumora Therapeutics presently has a consensus price target of $7.67, indicating a potential upside of 330.71%. Given Neumora Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Neumora Therapeutics is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neumora Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.56
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Neumora Therapeutics has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Neumora Therapeutics' return on equity of -181.70% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neumora Therapeutics	N/A	-181.70%	-119.15%
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Neumora Therapeutics. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.33	N/A
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A

47.7% of Neumora Therapeutics shares are owned by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 26.9% of Neumora Therapeutics shares are owned by company insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Neumora Therapeutics had 1 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 1 mentions for Neumora Therapeutics and 0 mentions for Calliditas Therapeutics AB (publ). Neumora Therapeutics' average media sentiment score of 1.89 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Neumora Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Neumora Therapeutics	Very Positive
Calliditas Therapeutics AB (publ)	Neutral

Neumora Therapeutics has a beta of 2.74, indicating that its share price is 174% more volatile than the broader market. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market.

Summary

Neumora Therapeutics beats Calliditas Therapeutics AB (publ) on 13 of the 16 factors compared between the two stocks.

How does Neumora Therapeutics compare to WAVE Life Sciences?

WAVE Life Sciences (NASDAQ:WVE) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends, media sentiment and valuation.

WAVE Life Sciences currently has a consensus target price of $26.41, indicating a potential upside of 349.94%. Neumora Therapeutics has a consensus target price of $7.67, indicating a potential upside of 330.71%. Given WAVE Life Sciences' stronger consensus rating and higher probable upside, equities analysts clearly believe WAVE Life Sciences is more favorable than Neumora Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.87
Neumora Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.56

Neumora Therapeutics has a net margin of 0.00% compared to WAVE Life Sciences' net margin of -255.70%. WAVE Life Sciences' return on equity of -56.76% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
WAVE Life Sciences	-255.70%	-56.76%	-42.80%
Neumora Therapeutics	N/A	-181.70%	-119.15%

WAVE Life Sciences has a beta of -1.33, indicating that its share price is 233% less volatile than the broader market. Comparatively, Neumora Therapeutics has a beta of 2.74, indicating that its share price is 174% more volatile than the broader market.

In the previous week, WAVE Life Sciences had 6 more articles in the media than Neumora Therapeutics. MarketBeat recorded 7 mentions for WAVE Life Sciences and 1 mentions for Neumora Therapeutics. Neumora Therapeutics' average media sentiment score of 1.89 beat WAVE Life Sciences' score of 0.88 indicating that Neumora Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
WAVE Life Sciences	Positive
Neumora Therapeutics	Very Positive

89.7% of WAVE Life Sciences shares are held by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are held by institutional investors. 24.3% of WAVE Life Sciences shares are held by company insiders. Comparatively, 26.9% of Neumora Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

WAVE Life Sciences has higher revenue and earnings than Neumora Therapeutics. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
WAVE Life Sciences	$42.73M	26.43	-$204.38M	-$1.06	N/A
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.33	N/A

Summary

WAVE Life Sciences beats Neumora Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Neumora Therapeutics compare to Collegium Pharmaceutical?

Collegium Pharmaceutical (NASDAQ:COLL) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, media sentiment, institutional ownership and profitability.

Collegium Pharmaceutical has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market. Comparatively, Neumora Therapeutics has a beta of 2.74, indicating that its stock price is 174% more volatile than the broader market.

Collegium Pharmaceutical has higher revenue and earnings than Neumora Therapeutics. Neumora Therapeutics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Collegium Pharmaceutical	$780.57M	1.44	$62.87M	$2.04	16.98
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.33	N/A

Collegium Pharmaceutical has a net margin of 9.41% compared to Neumora Therapeutics' net margin of 0.00%. Collegium Pharmaceutical's return on equity of 95.18% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Collegium Pharmaceutical	9.41%	95.18%	16.39%
Neumora Therapeutics	N/A	-181.70%	-119.15%

Collegium Pharmaceutical presently has a consensus price target of $57.50, suggesting a potential upside of 65.99%. Neumora Therapeutics has a consensus price target of $7.67, suggesting a potential upside of 330.71%. Given Neumora Therapeutics' higher probable upside, analysts plainly believe Neumora Therapeutics is more favorable than Collegium Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Collegium Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
Neumora Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.56

In the previous week, Collegium Pharmaceutical had 1 more articles in the media than Neumora Therapeutics. MarketBeat recorded 2 mentions for Collegium Pharmaceutical and 1 mentions for Neumora Therapeutics. Neumora Therapeutics' average media sentiment score of 1.89 beat Collegium Pharmaceutical's score of 0.93 indicating that Neumora Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Collegium Pharmaceutical	Positive
Neumora Therapeutics	Very Positive

47.7% of Neumora Therapeutics shares are held by institutional investors. 1.9% of Collegium Pharmaceutical shares are held by insiders. Comparatively, 26.9% of Neumora Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Collegium Pharmaceutical beats Neumora Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Neumora Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NMRA vs. The Competition

Export

Metric	Neumora Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$329.80M	$3.39B	$6.52B	$12.05B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-1.34	20.00	24.00	24.42
Price / Sales	N/A	306.82	514.36	111.24
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	2.87	8.32	10.54	6.82
Net Income	-$236.93M	$23.94M	$3.57B	$337.56M
7 Day Performance	9.88%	1.84%	0.60%	1.17%
1 Month Performance	-3.26%	-0.04%	1.56%	3.16%
1 Year Performance	110.78%	44.82%	25.42%	30.58%

Neumora Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NMRA Neumora Therapeutics	3.2569 of 5 stars	$1.78 flat	$7.67 +330.7%	+110.8%	$329.80M	N/A	N/A	108	Positive News
MPLT Maplight Therapeutics	3.5019 of 5 stars	$29.46 +5.2%	$37.78 +28.2%	N/A	$1.19B	N/A	N/A	109
COAG Hemab Therapeutics	4.5776 of 5 stars	$25.55 +1.0%	$41.75 +63.4%	N/A	$1.19B	N/A	N/A	72	Quiet Period Expiration Gap Up
CALT Calliditas Therapeutics AB (publ)	N/A	$40.00 flat	N/A	N/A	$1.19B	$1.60B	N/A	180
WVE WAVE Life Sciences	3.1204 of 5 stars	$5.70 -0.5%	$27.25 +378.1%	-15.5%	$1.10B	$42.73M	N/A	240

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NMRA) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Neumora Therapeutics (NMRA) Competitors

NMRA vs. MPLT, COAG, CALT, WVE, and COLL

How does Neumora Therapeutics compare to Maplight Therapeutics?

Summary

How does Neumora Therapeutics compare to Hemab Therapeutics?

Summary

How does Neumora Therapeutics compare to Calliditas Therapeutics AB (publ)?

Summary

How does Neumora Therapeutics compare to WAVE Life Sciences?

Summary

How does Neumora Therapeutics compare to Collegium Pharmaceutical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NMRA vs. The Competition

Neumora Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Neumora Therapeutics (NMRA) Competitors

NMRA vs. MPLT, COAG, CALT, WVE, and COLL

How does Neumora Therapeutics compare to Maplight Therapeutics?

Does the media refer more to NMRA or MPLT?

Do analysts recommend NMRA or MPLT?

Do institutionals and insiders hold more shares of NMRA or MPLT?

Is NMRA or MPLT more profitable?

Which has preferable valuation and earnings, NMRA or MPLT?

Summary

How does Neumora Therapeutics compare to Hemab Therapeutics?

Which has stronger valuation and earnings, NMRA or COAG?

Does the media favor NMRA or COAG?

Do analysts rate NMRA or COAG?

Is NMRA or COAG more profitable?

Do institutionals and insiders have more ownership in NMRA or COAG?

Summary

How does Neumora Therapeutics compare to Calliditas Therapeutics AB (publ)?

Do analysts recommend NMRA or CALT?

Is NMRA or CALT more profitable?

Which has preferable valuation & earnings, NMRA or CALT?

Do institutionals & insiders believe in NMRA or CALT?

Does the media refer more to NMRA or CALT?

Which has more volatility & risk, NMRA or CALT?

Summary

How does Neumora Therapeutics compare to WAVE Life Sciences?

Do analysts prefer WVE or NMRA?

Is WVE or NMRA more profitable?

Which has more volatility & risk, WVE or NMRA?

Does the media prefer WVE or NMRA?

Do institutionals & insiders believe in WVE or NMRA?

Which has higher valuation & earnings, WVE or NMRA?

Summary

How does Neumora Therapeutics compare to Collegium Pharmaceutical?

Which has more risk and volatility, COLL or NMRA?

Which has stronger earnings and valuation, COLL or NMRA?

Is COLL or NMRA more profitable?

Do analysts rate COLL or NMRA?

Does the media prefer COLL or NMRA?

Do insiders and institutionals have more ownership in COLL or NMRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NMRA vs. The Competition

Neumora Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools